Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2015 | 09-2015 | 06-2015 | 03-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -46,991 | -33,567 | -19,865 | -10,167 | -36,412 |
| Depreciation Amortization | 6,579 | 6,917 | 3,507 | 1,645 | 8,680 |
| Income taxes - deferred | -4,516 | -3,395 | -2,448 | -1,177 | -7,376 |
| Accounts receivable | -80 | 98 | 69 | 171 | -63 |
| Other Working Capital | 3,305 | -44 | 806 | 1,139 | -827 |
| Other Operating Activity | -2,841 | -606 | -1,105 | -680 | -2,856 |
| Operating Cash Flow | $-44,544 | $-30,597 | $-19,036 | $-9,069 | $-38,854 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -5,334 | -4,344 | -2,823 | -373 | -693 |
| Purchase Of Investment | -1,248 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -859 | -509 | -3 | 0 | -315 |
| Investing Cash Flow | $-7,441 | $-4,853 | $-2,826 | $-373 | $-1,008 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 255 | 188 | 188 | N/A | 471 |
| Debt Repayment | -59 | -31 | -28 | -14 | -26 |
| Common Stock Issued | 61,483 | 33,107 | 23,949 | 5,847 | 60,001 |
| Other Financing Activity | 3,096 | 1,967 | -37 | -149 | 3,177 |
| Financing Cash Flow | $64,775 | $35,231 | $24,072 | $5,684 | $63,623 |
| Exchange Rate Effect | -48 | 110 | -232 | 101 | 230 |
| Beginning Cash Position | 29,487 | 29,487 | 29,487 | 29,487 | 5,496 |
| End Cash Position | 42,229 | 29,378 | 31,465 | 25,830 | 29,487 |
| Net Cash Flow | $12,742 | $-109 | $1,978 | $-3,657 | $23,991 |
| Free Cash Flow | |||||
| Operating Cash Flow | -44,544 | -30,597 | -19,036 | -9,069 | -38,854 |
| Capital Expenditure | -5,334 | -4,344 | -2,823 | -373 | -702 |
| Free Cash Flow | -49,878 | -34,941 | -21,859 | -9,442 | -39,556 |